Expression of EYA2 in non-small cell lang cancer
JT Guo, LH Ding, CY Liang, NK Zhou… - Zhonghua Zhong liu za …, 2009 - europepmc.org
JT Guo, LH Ding, CY Liang, NK Zhou, QN Ye
Zhonghua Zhong liu za zhi [Chinese Journal of Oncology], 2009•europepmc.orgObjective To identify the expression of Drosophila Eyes Absent Homologue 2 (EYA2) in non-
small cell lung cancer (NSCLC) and to investigate its correlation with clinical parameters.
Methods 59 fresh specimens of lung cancer and paired normal lung tissue were obtained
from 59 NSCLC cases treated in the department of thoracic surgery in our hospital from June
2006 to October 2007. Western blotting and immunohistochemistry were used to assay the
specimens with goat anti-human EYA2 polyclone antibody. Clinicopathological parameters …
small cell lung cancer (NSCLC) and to investigate its correlation with clinical parameters.
Methods 59 fresh specimens of lung cancer and paired normal lung tissue were obtained
from 59 NSCLC cases treated in the department of thoracic surgery in our hospital from June
2006 to October 2007. Western blotting and immunohistochemistry were used to assay the
specimens with goat anti-human EYA2 polyclone antibody. Clinicopathological parameters …
Objective
To identify the expression of Drosophila Eyes Absent Homologue 2 (EYA2) in non-small cell lung cancer (NSCLC) and to investigate its correlation with clinical parameters.
Methods
59 fresh specimens of lung cancer and paired normal lung tissue were obtained from 59 NSCLC cases treated in the department of thoracic surgery in our hospital from June 2006 to October 2007. Western blotting and immunohistochemistry were used to assay the specimens with goat anti-human EYA2 polyclone antibody. Clinicopathological parameters were collected and the correlation with EYA2 expression was subsequently analyzed.
Results
The expression of EYA2 was detected in cytoplasm and nucleus of the cancer cells, but mostly in cytoplasm. Western blotting and immunohistochemistry showed the expression of EYA2 in NSCLC was increased and correlated with pathological type, but not with gender, age, pTNM stage, histological differentiation and lymph node metastasis. EYA2 expression was significantly up-regulated in adenocarcinoma, while not changed in lung squamous cell carcinoma.
Conclusion
The results of this study suggest that expression of EYA2 in lung adenocarcinoma is augmented. EYA2 is likely participating in the development of lung adenocarcinoma as a transcriptional activator.
europepmc.org